首页 › 基金 › IRIDIAN ASSET MANAGEMENT LLC/CT › BCTX
IRIDIAN ASSET MANAGEMENT LLC/CT 对 BCTX 的持仓历史
BRIACELL THERAPEUTICS CORP · 医疗保健
IRIDIAN ASSET MANAGEMENT LLC/CT 在 Q3 2026 的 13F 申报中披露持有 BCTX(BRIACELL THERAPEUTICS CORP)65,000 股,市值约 US$278K,约占其申报组合的 0.10%,在其申报持仓中市值排名第 40 位。 IRIDIAN ASSET MANAGEMENT LLC/CT 最近 3 个申报季度中有 3 个季度披露了 BCTX 持仓,最早可追溯至 Q1 2026。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
IRIDIAN ASSET MANAGEMENT LLC/CT 对 BCTX 的持仓演变
IRIDIAN ASSET MANAGEMENT LLC/CT 于 Q1 2026 首次披露 BCTX 持仓:65,000 股(约 US$272K)。 该持仓在 Q3 2026 达到峰值 65,000 股,市值约 US$278K。 在 3 次申报中,IRIDIAN ASSET MANAGEMENT LLC/CT 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 65,000 股、市值约 US$278K。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2026 | 65.00K | $272.35K | 新进 |
| Q2 2026 | 65.00K | $210.60K | 持有 |
| Q3 2026 | 65.00K | $278.20K | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 BCTX 与 13F 数据
BCTX(BRIACELL THERAPEUTICS CORP)属于医疗保健行业。我们追踪的基金中还有 17 只申报持有 BCTX。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
更多关于 IRIDIAN ASSET MANAGEMENT LLC/CT
常见问题
How long has IRIDIAN ASSET MANAGEMENT LLC/CT held BCTX?
IRIDIAN ASSET MANAGEMENT LLC/CT has disclosed BCTX holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is IRIDIAN ASSET MANAGEMENT LLC/CT's current position in BCTX?
As of Q3 2026, IRIDIAN ASSET MANAGEMENT LLC/CT holds 65.00K shares of BCTX (BRIACELL THERAPEUTICS CORP), valued at $278.20K, representing 0.10% of its reported portfolio and ranking #40.
Has IRIDIAN ASSET MANAGEMENT LLC/CT been buying or selling BCTX?
In the latest 13F filing (Q3 2026), IRIDIAN ASSET MANAGEMENT LLC/CT held unchanged its position in BCTX. The position peaked in Q3 2026 at 65.00K shares.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.